Efficacy and safety of vedolizumab in the treatment of ulcerative colitis

被引：4

作者：

Domenech, Eugeni ^{[1
,3
]}

Gisbert, Javier P. ^{[2
,3
]}

机构：

[1] Hosp Badalona Germans Trias & Pujol, Serv Aparato Digest, Badalona, Spain

[2] Hosp Univ La Princesa, Inst Invest Sanitaria Princesa IIS IP, Serv Aparato Digest, Madrid, Spain

[3] Ctr Invest Biomed Red Enfermedades Hepat & Digest, Madrid, Spain

来源：

Gastroenterologia y Hepatologia | 2016年 / 39卷 / 10期

关键词：

Ulcerative colitis; Vedolizumab; Inflammatory bowel disease; Integrins; Adhesion molecules; INFLAMMATORY-BOWEL-DISEASE; MICROVASCULAR ENDOTHELIAL-CELLS; CROHNS-DISEASE; ADHESION MOLECULES; GEMINI; MAINTENANCE THERAPY; ANTI-TNF; MECHANISMS; INDUCTION; REMISSION;

D O I：

10.1016/j.gastrohep.2015.11.010

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Integrins play a crucial role in the development and maintenance of the inflammatory process in patients with inflammatory bowel disease. Vedolizumab is a humanized monoclonal antibody with a predominantly gastrointestinal effect. It specifically inhibits leukocyte integrin alpha(4)beta(7), thus preventing its interaction with mucosal vascular addressin cell adhesion molecule 1(MAdCAM-1), which is involved in the migration of lymphocytes from the blood stream to the intestinal tissue. Vedolizumab is indicated in the treatment of moderate to severe active Crohn's disease and ulcerative colitis in adult patients with poor response, loss of response, or intolerance to conventional treatment or to tumour necrosis factor alpha (TNF-alpha) antagonists. This review presents the most relevant clinical outcomes of vedolizumab in the treatment of patients with ulcerative colitis. (C) 2016 Elsevier Espana, S.L.U. and AEEH y AEG. All rights reserved.

引用

页码：677 / 686

页数：10

共 50 条

[1] The safety of vedolizumab for the treatment of ulcerative colitis
Novak, Gregor
Hindryckx, Pieter
Khanna, Reena
Jairath, Vipul
Feagan, Brian G.
[J]. EXPERT OPINION ON DRUG SAFETY, 2017, 16 (04) : 501 - 507
[2] Efficacy and safety of vedolizumab in the maintenance phase of ulcerative colitis
Torralba, K. S.
Payawal, D. A.
[J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2021, 36 : 267 - 268
[3] Efficacy and safety of retreatment with vedolizumab in patients with ulcerative colitis
Sands, B. E.
Shafran, I.
Farraye, F. A.
Cheifetz, A. S.
Abhyankar, B.
Sankoh, S.
Smyth, M.
[J]. JOURNAL OF CROHNS & COLITIS, 2015, 9 : S37 - S37
[4] EFFICACY AND SAFETY OF VEDOLIZUMAB IN THE TREATMENT OF ULCERATIVE COLITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS
Thode, R.
Veeranki, P.
Inuganti, A.
Paladugu, G.
Hyderboini, R. K.
Kolapalli, N.
Vsn, M.
Dang, D.
Dang, A.
[J]. VALUE IN HEALTH, 2018, 21 : S82 - S82
[5] Vedolizumab for the treatment of ulcerative colitis
Stallmach, Andreas
Schmidt, Carsten
Teich, Niels
[J]. EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2016, 10 (02) : 165 - 175
[6] Vedolizumab for the treatment of ulcerative colitis
Shahidi, Neal
Bressler, Brian
Panaccione, Remo
[J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2016, 16 (01) : 129 - 135
[7] Vedolizumab for the treatment of ulcerative colitis
Rietdijk, Svend T.
D'Haens, Geert R.
[J]. EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2014, 7 (04) : 423 - 430
[8] Safety of vedolizumab in the treatment of Crohn's disease and ulcerative colitis
Hagan, Matilda
Cross, Raymond K.
[J]. EXPERT OPINION ON DRUG SAFETY, 2015, 14 (09) : 1473 - 1479
[9] Vedolizumab in the Treatment of Ulcerative Colitis: An Evidence-Based Review of Safety, Efficacy, and Place of Therapy
Takatsu, Noritaka
Hisabe, Takashi
Higashi, Daijiro
Ueki, Toshiharu
Matsui, Toshiyuki
[J]. CORE EVIDENCE, 2020, 15 : 7 - 20
[10] Predictors of the efficacy of vedolizumab in patients with ulcerative colitis
Kajikawa, Go
Sawada, Tsunaki
Nakamura, Masanao
Yamamura, Takeshi
Maeda, Keiko
Ishikawa, Eri
Uetsuki, Kota
Hirose, Takashi
Iida, Tadashi
Mizutani, Yasuyuki
Yamao, Kentaro
Ishikawa, Takuya
Furukawa, Kazuhiro
Kawashima, Hiroki
[J]. NAGOYA JOURNAL OF MEDICAL SCIENCE, 2024, 86 (03): : 407 - 421

← 1 2 3 4 5 →